Wharton Business Group LLC continued to hold its stake in Emergent Biosolutions, Inc. (NYSE:EBS) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,927 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Wharton Business Group LLC’s holdings in Emergent Biosolutions were worth $404,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Riverhead Capital Management LLC lifted its stake in Emergent Biosolutions by 102.8% in the second quarter. Riverhead Capital Management LLC now owns 3,042 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 1,542 shares during the last quarter. State of Alaska Department of Revenue lifted its stake in Emergent Biosolutions by 2.7% in the first quarter. State of Alaska Department of Revenue now owns 3,820 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 100 shares during the last quarter. Creative Planning lifted its stake in Emergent Biosolutions by 1.2% in the second quarter. Creative Planning now owns 4,555 shares of the biopharmaceutical company’s stock valued at $154,000 after acquiring an additional 55 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in Emergent Biosolutions by 17.3% in the first quarter. Envestnet Asset Management Inc. now owns 5,710 shares of the biopharmaceutical company’s stock valued at $165,000 after acquiring an additional 844 shares during the last quarter. Finally, Mason Street Advisors LLC lifted its stake in Emergent Biosolutions by 7.5% in the first quarter. Mason Street Advisors LLC now owns 8,087 shares of the biopharmaceutical company’s stock valued at $235,000 after acquiring an additional 564 shares during the last quarter. Hedge funds and other institutional investors own 85.44% of the company’s stock.

Shares of Emergent Biosolutions, Inc. (EBS) traded down 0.3549% during mid-day trading on Monday, reaching $37.5064. 64,857 shares of the company’s stock were exchanged. Emergent Biosolutions, Inc. has a 52-week low of $24.47 and a 52-week high of $38.00. The company has a market cap of $1.55 billion, a PE ratio of 23.8894 and a beta of 1.23. The company’s 50-day moving average price is $35.89 and its 200 day moving average price is $32.34.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.26 by $0.13. The firm had revenue of $100.77 million for the quarter, compared to analysts’ expectations of $111.57 million. Emergent Biosolutions had a return on equity of 14.50% and a net margin of 13.42%. Emergent Biosolutions’s revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.05) earnings per share. On average, equities research analysts predict that Emergent Biosolutions, Inc. will post $1.54 EPS for the current year.

In other Emergent Biosolutions news, Chairman Fuad El-Hibri sold 16,439 shares of Emergent Biosolutions stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $37.50, for a total transaction of $616,462.50. Following the transaction, the chairman now directly owns 1,605,216 shares of the company’s stock, valued at approximately $60,195,600. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jerome M. Hauer sold 10,776 shares of Emergent Biosolutions stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $35.83, for a total transaction of $386,104.08. Following the transaction, the director now directly owns 29,421 shares in the company, valued at $1,054,154.43. The disclosure for this sale can be found here. Insiders have sold a total of 100,776 shares of company stock worth $3,681,754 over the last ninety days. Insiders own 16.50% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/11/wharton-business-group-llc-has-404000-stake-in-emergent-biosolutions-inc-ebs.html.

A number of analysts have commented on the stock. BidaskClub upgraded shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Friday, August 25th. Zacks Investment Research cut shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $44.00.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions, Inc. (NYSE:EBS).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Stock Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related stocks with our FREE daily email newsletter.